When to get bloodwork on peptides

Guide 5 min read Reviewed

Baseline panels, optimal recheck timing, which markers matter for which compounds, and why the time of your blood draw relative to your last dose changes everything.

Contents7
  1. 1The bloodwork timeline
  2. 2Which panels for which compounds
  3. 3Why trough timing matters for hormones
  4. 4Fasting requirements
  5. 5Where to get bloodwork
  6. 6Reading your results
  7. 7References

Bloodwork measures what is happening at the biomarker level. Subjective markers (energy, mood, recovery) are useful for tracking trends, but they cannot show hematocrit, hormone levels, or whether metabolic markers are moving.

The question this page looks at is when a draw is taken, which depends on what is being run and what the draw is meant to show.

The bloodwork timeline

This page lays the timing out in three phases. The specific timing varies by compound.

Baseline: before starting

A baseline panel is taken before the first dose and is the reference point. Without baseline numbers, compound effects cannot be told apart from pre-existing levels. The Xyosted testosterone label, for example, says to check that hematocrit is not elevated before starting.5

First recheck: 4 to 6 weeks

By their labels, semaglutide reaches steady state after 4 to 5 weeks of once-weekly doses and tirzepatide after 4 weeks.12 The Xyosted label measures testosterone trough concentrations after 6 weeks of dosing and says steady state was reached by week 6.5 A draw at that point reflects the regular schedule rather than the ramp-up.

Periodic monitoring

For testosterone, the Endocrine Society guideline describes a standardized monitoring plan that measures serum testosterone and hematocrit and evaluates prostate cancer risk during the first year.4 The Xyosted label says to evaluate hematocrit approximately every 3 months while on treatment.5 Repeated draws show gradual shifts that a single comparison might miss.

Which panels for which compounds

Different compound categories are linked to different biomarkers in their labels and trials.

Testosterone & hormone protocols

Testosterone has a published monitoring plan in the Endocrine Society guideline.4 The Xyosted label says to monitor hematocrit, PSA and lipids, and the Depo-Testosterone label says hemoglobin and hematocrit should be checked periodically with long-term use and that serum cholesterol may increase.56 The guideline recommends a free testosterone measure when total testosterone is near the lower limit or SHBG is altered.4

Total Testosterone, Free Testosterone, Estradiol (E2), SHBG, Hematocrit (HCT), Hemoglobin, Lipid Panel (HDL/LDL/Triglycerides), PSA, Liver Panel (AST/ALT)
Timing: The Xyosted label measures trough concentrations, 7 days after the most recent weekly dose.5 For twice-weekly schedules, the trough is the morning of the injection day, before injecting.

GLP-1 receptor agonists

The Wegovy label reports mean increases from baseline in amylase of 15% to 16% and lipase of 39% in its weight-reduction trials, and says routine monitoring of serum calcitonin is of uncertain value.3 Glucose and HbA1c are the measures used in the type 2 diabetes labels.1

Fasting Glucose, HbA1c, Fasting Insulin, Comprehensive Metabolic Panel, Lipid Panel, Thyroid Panel (TSH, Free T3, Free T4), Amylase/Lipase
Timing: Fasting draw. Semaglutide's label gives an elimination half-life of approximately 1 week, so its levels move less across the week than a shorter-acting compound's.1

General peptides (BPC-157, TB-500, GHK-Cu, etc.)

No published monitoring plan was found for healing and cosmetic peptides like these, and they are not measured on standard blood tests. General health markers are the panel left to look at.

CBC, CMP, Liver Panel (AST/ALT), Kidney Function (BUN/Creatinine), C-Reactive Protein (CRP, for inflammation tracking)
Timing: No specific timing relative to dose. A fasting draw keeps conditions consistent.

GH secretagogues (CJC-1295, ipamorelin, etc.)

In a trial in healthy adults, single injections of CJC-1295 raised mean IGF-I 1.5- to 3-fold for 9 to 11 days.8

IGF-1, Fasting Glucose, Fasting Insulin, HbA1c, Liver Panel
Timing: Morning fasting draw. A 2026 review describes serum IGF-1 as a stable indication of integrated GH secretion, while GH itself is released in a dynamic pattern.7

Why trough timing matters for hormones

For testosterone, the time of the draw relative to the last dose changes the result. On the Xyosted label (weekly testosterone enanthate under the skin), testosterone peaked a median of 11.9 hours after the dose; at week 12 the mean peak was 790 ng/dL and the mean low point 436 ng/dL.5

The Xyosted label bases dose changes on the trough concentration, measured 7 days after the most recent dose.5 A trough draw taken the same way each time is comparable across time periods: a week-6 trough can be read against a week-12 trough.

Draws at random times relative to the dose are harder to read. A higher reading might mean levels have risen, or only that the draw came closer to the last injection. The same draw timing removes this variable.

Example

With testosterone injected twice a week (say Monday and Thursday), the trough falls on Thursday morning, before the Thursday injection. The saturation level on draw day shows where in the concentration curve the draw was taken.

Fasting requirements

Some markers are read fasted. How much it matters differs by marker:

  • Glucose and insulin: fasting glucose and fasting insulin are, by name, fasted tests.
  • Lipids: a 2016 European consensus found the largest mean change 1 to 6 hours after usual meals was +0.3 mmol/L for triglycerides, called not clinically significant, and recommends non-fasting samples for routine lipid profiles.9
  • Metabolic panels: a fasted draw keeps baseline and later numbers comparable.

For diagnosing low testosterone, the Endocrine Society recommends fasting morning total testosterone.4 Drawing fasted at the same time of day keeps conditions consistent across panels and timepoints.

Where to get bloodwork

Options vary by country, but the general categories are:

  • Direct-to-consumer labs: Services that let a person order panels without a doctor's order and walk into a lab for a draw. Availability differs by country.
  • GP / Primary care: A doctor can order panels, though compound-specific markers may need context.
  • Telehealth clinics: Some TRT and peptide clinics include periodic bloodwork in their service.

Whatever the source, results that include reference ranges, and copies kept over time, allow comparison later.

Reading your results

Two principles for interpreting bloodwork on any protocol:

  1. Trends matter more than single readings. One high or low value is a data point. A consistent pattern across several draws is a trend.
  2. Compare to your own baseline, not just the reference range. A reference range describes a population. A pre-protocol baseline describes one person, so it is the closer comparison.

Logging bloodwork results alongside your protocol data (dose history, saturation levels, subjective check-ins) creates a complete picture that none of those data streams provide alone.

References

  1. Novo Nordisk (DailyMed). Ozempic (semaglutide) injection label. 2026. dailymed.nlm.nih.gov
  2. Eli Lilly (DailyMed). Mounjaro (tirzepatide) injection label. 2026. dailymed.nlm.nih.gov
  3. Novo Nordisk (DailyMed). Wegovy (semaglutide) label. 2026. dailymed.nlm.nih.gov
  4. Bhasin S et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018. pubmed.ncbi.nlm.nih.gov
  5. Antares Pharma (DailyMed). Xyosted (testosterone enanthate) injection label. 2026. dailymed.nlm.nih.gov
  6. Pharmacia & Upjohn (DailyMed). Depo-Testosterone (testosterone cypionate) injection label. 2026. dailymed.nlm.nih.gov
  7. Cardoso LM et al. Acromegaly: biochemical diagnosis. Vitam Horm. 2026. pubmed.ncbi.nlm.nih.gov
  8. Teichman SL et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006. pubmed.ncbi.nlm.nih.gov
  9. Nordestgaard BG et al. Fasting is not routinely required for determination of a lipid profile. Eur Heart J. 2016. pubmed.ncbi.nlm.nih.gov